Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016908 · ClinicalTrials.gov registry record
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
A clinical trial of Duchenne Muscular Dystrophy, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT05016908: Recruiting study of Duchenne Muscular Dystrophy, sponsored by Massachusetts General Hospital.
NCT05016908 is a study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 410-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05016908, a study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.
Primary Outcome
The extracellular RNA biomarkers in the muscular dystrophy groups will be evaluated and compared with the extracellular RNA content in control groups. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers as measurements of disease activity and severity.
Conditions Studied
Study Locations (2)
Massachusetts
- Boston Children's Hospital - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-11-30 |
| Est. Completion | 2027-11 |
What NCT05016908 shows while recruiting
NCT05016908 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 410-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT05016908 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05016908 about?
NCT05016908 is a clinical study titled "Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy". Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is t...
What is the current status of trial NCT05016908?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2019-11-30. Estimated completion is 2027-11.
What conditions does trial NCT05016908 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
Who is sponsoring clinical trial NCT05016908?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05016908 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05016908's enrollment target sits among peer trials
100 14th of 48 higher than 35 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI